Oral SERD, A Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against ESR1 mutant tumors. However, due to its poor bioavailability and need for intramuscular injection, it may not be the optimal therapy for patients.
 
 Second-generation SERDs have been developed to overcome these limitations. These newer drugs have improved oral bioavailability and pharmacokinetics, making them more convenient and effective for patients. Several oral SERDs are now in phase III trials for early and advanced ER+ breast cancer. This review summarizes the background of oral SERD development, the current status, and future perspectives..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Preprints.org - (2024) vom: 06. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Neupane, Niraj [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.20944/preprints202311.1826.v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
preprintsorg04170066X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | preprintsorg04170066X | ||
| 003 | DE-627 | ||
| 005 | 20240207135026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20944/preprints202311.1826.v1 |2 doi | |
| 024 | 7 | |a 10.20944/preprints202311.1826.v1 |2 doi | |
| 035 | |a (DE-627)preprintsorg04170066X | ||
| 035 | |a (preprintsorg)10.20944/preprints202311.1826 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Neupane, Niraj |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral SERD, A Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against ESR1 mutant tumors. However, due to its poor bioavailability and need for intramuscular injection, it may not be the optimal therapy for patients.
 
 Second-generation SERDs have been developed to overcome these limitations. These newer drugs have improved oral bioavailability and pharmacokinetics, making them more convenient and effective for patients. Several oral SERDs are now in phase III trials for early and advanced ER+ breast cancer. This review summarizes the background of oral SERD development, the current status, and future perspectives. | ||
| 700 | 1 | |a Bawek, Sawyer |4 aut | |
| 700 | 1 | |a Gurusinghe, Sayuri |4 aut | |
| 700 | 1 | |a Ghaffary, Elham Moases |4 aut | |
| 700 | 1 | |a Mirmosayyeb, Omid |4 aut | |
| 700 | 1 | |a Thapa, Sangharsha |4 aut | |
| 700 | 1 | |a Falkson, Carla |4 aut | |
| 700 | 1 | |a O’Regan, Ruth |4 aut | |
| 700 | 1 | |a Dhakal, Ajay |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Preprints.org |g (2024) vom: 06. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:06 |g month:02 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers16030619 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20944/preprints202311.1826.v1 |z kostenfrei |3 Volltext |
| 912 | |a preprintsorg | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 06 |c 02 | ||